DE60223688T2 - Verfahren zur behandlung von multiplem myelom - Google Patents

Verfahren zur behandlung von multiplem myelom Download PDF

Info

Publication number
DE60223688T2
DE60223688T2 DE60223688T DE60223688T DE60223688T2 DE 60223688 T2 DE60223688 T2 DE 60223688T2 DE 60223688 T DE60223688 T DE 60223688T DE 60223688 T DE60223688 T DE 60223688T DE 60223688 T2 DE60223688 T2 DE 60223688T2
Authority
DE
Germany
Prior art keywords
antibody
cells
kappa
seq
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223688T
Other languages
German (de)
English (en)
Other versions
DE60223688D1 (de
Inventor
Robert Lindsay Pennant Hills RAISON
Rosanne Dorothy Seaforth DUNN
Boon Hwa Andre 12-238 CHOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNE SYSTEMS THERAPEUTICS Ltd
Immune System Therapeutics Ltd
Original Assignee
IMMUNE SYSTEMS THERAPEUTICS Ltd
Immune System Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNE SYSTEMS THERAPEUTICS Ltd, Immune System Therapeutics Ltd filed Critical IMMUNE SYSTEMS THERAPEUTICS Ltd
Application granted granted Critical
Publication of DE60223688D1 publication Critical patent/DE60223688D1/de
Publication of DE60223688T2 publication Critical patent/DE60223688T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60223688T 2001-07-06 2002-07-05 Verfahren zur behandlung von multiplem myelom Expired - Lifetime DE60223688T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR617901 2001-07-06
AUPR6179A AUPR617901A0 (en) 2001-07-06 2001-07-06 Method for treating multiple myeloma
PCT/AU2002/000896 WO2003004056A1 (en) 2001-07-06 2002-07-05 Method for treating multiple myeloma

Publications (2)

Publication Number Publication Date
DE60223688D1 DE60223688D1 (de) 2008-01-03
DE60223688T2 true DE60223688T2 (de) 2008-10-30

Family

ID=3830143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223688T Expired - Lifetime DE60223688T2 (de) 2001-07-06 2002-07-05 Verfahren zur behandlung von multiplem myelom

Country Status (13)

Country Link
US (3) US7344715B2 (https=)
EP (1) EP1414492B1 (https=)
JP (1) JP4535424B2 (https=)
CN (1) CN1551783B (https=)
AU (1) AUPR617901A0 (https=)
CA (1) CA2461989C (https=)
DE (1) DE60223688T2 (https=)
DK (1) DK1414492T3 (https=)
ES (1) ES2296952T3 (https=)
MX (1) MXPA04000130A (https=)
NZ (1) NZ530099A (https=)
WO (1) WO2003004056A1 (https=)
ZA (1) ZA200400959B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
NZ548921A (en) * 2004-02-27 2008-09-26 Immune System Therapeutics Ltd Target for B-cell disorders
AU2005318407B2 (en) 2004-12-23 2009-11-05 F. Hoffmann-La Roche Ag Detection of a therapeutic antibody in an experimental animal
GB0608444D0 (en) * 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
HUE031944T2 (en) 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
JP5599454B2 (ja) 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN103068852B (zh) 2010-08-17 2016-04-20 弗·哈夫曼-拉罗切有限公司 抗人IgG1抗体
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
EP3286223B8 (en) 2015-04-23 2024-04-03 HaemaLogiX Ltd Kappa myeloma antigen chimeric antigen receptors and uses thereof
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
KR20210142088A (ko) * 2018-12-03 2021-11-24 해마로직스 피티와이. 리미티드 치료방법
EP4126900A4 (en) * 2020-03-27 2024-05-29 Haemalogix Ltd Composition and method
JP2023085151A (ja) * 2021-12-08 2023-06-20 株式会社八神製作所 体外ホウ素中性子反応を用いた幹細胞の分取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma

Also Published As

Publication number Publication date
EP1414492B1 (en) 2007-11-21
JP4535424B2 (ja) 2010-09-01
ES2296952T3 (es) 2008-05-01
CN1551783B (zh) 2010-11-03
US7556803B2 (en) 2009-07-07
DK1414492T3 (da) 2008-04-07
US20080199463A1 (en) 2008-08-21
AUPR617901A0 (en) 2001-08-02
US7838041B2 (en) 2010-11-23
NZ530099A (en) 2006-04-28
US7344715B2 (en) 2008-03-18
WO2003004056A1 (en) 2003-01-16
CA2461989A1 (en) 2003-01-16
CA2461989C (en) 2011-11-15
ZA200400959B (en) 2005-04-26
MXPA04000130A (es) 2005-06-06
DE60223688D1 (de) 2008-01-03
JP2005504018A (ja) 2005-02-10
US20090263358A1 (en) 2009-10-22
EP1414492A1 (en) 2004-05-06
AU2006202148A1 (en) 2006-06-08
CN1551783A (zh) 2004-12-01
US20040214761A1 (en) 2004-10-28
EP1414492A4 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
DE60223688T2 (de) Verfahren zur behandlung von multiplem myelom
DE60038252T2 (de) Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
DE69838454T2 (de) Natürlicher menschlicher antikörper
DE69735888T2 (de) Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann
DE69331903T2 (de) Veränderte Antikörper, damit zusammenhängende Produkte und Verfahren
DE69531148T2 (de) Bibliotheken aus polyklonalen antikörpern
DE60226036T3 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
DE69518919T2 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
DE69530763T2 (de) Antikörper gegen e-selektin
DE69530975T2 (de) Rekombinante humanisierte antikörper gegen lewis y
DE69922261T2 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE69925909T2 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE69800716T2 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DE69433563T2 (de) Gegen das ca55.1 antigen gerichtete bindende strukturen
DE69226990T2 (de) Tumorantigen-spezifischer Antikörper
DE69431602T2 (de) Monoklonale antikörper zur diagnose und behandlung von kolorektalkrebs
DE69830492T2 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
DE69824234T2 (de) Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2
WO1991017248A1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE69528624T2 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
DE69828154T2 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE60214127T2 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
EP0537489A1 (de) Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69334036T2 (de) Hybridom und humanisierter momoklonaler Anti-KC-4-Antikörper, dafür kodierende DNA und RNA, Kit und diagnostische Verfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition